Prof Dr Barbara Rothen-Rutishauser received her PhD in 1996 in cell biology at the Swiss Federal Institute of Technology (ETH) in Zurich. From 1996 to 2000 she held a post-doctoral position in Biopharmacy at ETH and in 2000 she joined Prof Peter Gehr’s research group at the University of Bern, Switzerland, as a postdoc. After promotion to group leader in 2006 she completed her habilitation in cell biology in 2009. Prof Rothen-Rutishauser has pioneered the development of 3D human lung models to assess effects of aerosolised drugs and nanoparticles.
Since 2011, she has been the new chair in BioNanomaterials at the Adolphe Merkle Institute, University of Fribourg, Switzerland, equally sharing the position with Prof Alke Fink. Prof Rothen-Rutishauser has published more than 220 peer-reviewed papers and is an associate editor of the journal Particle and Fibre Toxicology, and is also on the board of many other journals, such as Nanotoxicology and JAMPDD. She served as a board member for ISAM from 2011–2015 and as the conference Chair of the 2019 biennial conference in Montreux, Switzerland.